Working… Menu
Trial record 2 of 319 for:    FLUTICASONE AND SALMETEROL

A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg Twice Daily To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg Twice Daily In Symptomatic Patients With Asthma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00452348
Recruitment Status : Completed
First Posted : March 27, 2007
Results First Posted : February 15, 2010
Last Update Posted : December 9, 2016
Information provided by (Responsible Party):

Brief Summary:
This purpose of this study is to show the superiority and long term safety and efficacy of adding a long acting beta agonist (salmeterol) to constant dose of an inhaled corticosteroid (fluticasone propionate) in symptomatic subjects with asthma. The 12-month assessment of asthma control will provide key information on the efficacy and safety of the combination therapy. The safety measure will be an assessment of adverse events

Condition or disease Intervention/treatment Phase
Asthma Drug: Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID Drug: Fluticasone propionate 250 mcg BID Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 628 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A 52-week, Randomized, Double-Blind, Parallel-Group Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product (FSC) 250/50 mcg BID and Fluticasone Propionate (FP) DISKUS 250 mcg BID in Treatment of Subjects With Asthma
Study Start Date : May 2007
Actual Primary Completion Date : April 2009
Actual Study Completion Date : April 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma

Arm Intervention/treatment
Active Comparator: Fluticasone propionate 250 mcg BID
Fluticasone propionate 250 mcg BID
Drug: Fluticasone propionate 250 mcg BID
Fluticasone propionate 250 mcg BID

Active Comparator: Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID
Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID
Drug: Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID
Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID
Other Name: Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID and Fluticasone propionate 250 mcg BID

Primary Outcome Measures :
  1. Mean Change From Baseline in Pre-dose FEV1 Over Weeks 1-52 [ Time Frame: Baseline and Week 1 through Week 52 ]
    Pulmonary function was measured by forced expiratory volume in one second (FEV1), which is the volume of air exhaled from the lungs in one second. Change from baseline was calculated as the average of the Week 1 through Week 52 values minus the baseline value.

Secondary Outcome Measures :
  1. Mean Change From Baseline in AM PEF Over Weeks 1-52 [ Time Frame: Baseline and Week 1 through Week 52 ]
    Morning (AM) peak expiratory flow (PEF) is defined as the maximum volume of air exhaled in liters per minute. Change from baseline was calculated as the average of the Week 1 through Week 52 values minus the baseline value.

  2. Mean Change From Baseline in the Percentage of Symptom-free Days Over Weeks 1-52 [ Time Frame: Baseline and Week 1 through Week 52 ]
    A symptom-free day was defined as a day without asthma symptoms, as measured via the daily asthma symptom score (measuring symptoms during the day and previous night) on a 6-point scale (ranging from 0 to 5). A symptom score of 0=no symptoms, 1=symptoms for one short period, 2=symptoms for two or more short periods, 3=symptoms that did not affect normal daily activities, 4=symptoms that did affect normal daily activities, 5=symptoms so severe that daily activities could not be performed. Change from baseline was calculated as the average of the Week 1-Week 52 values minus the baseline value.

  3. Rate of Asthma Attacks Per Participant Per Year [ Time Frame: Week 1 through Week 52 ]
    The rate of asthma attacks was defined as the mean number of attacks per participant per year. An asthma attack was defined as a >=20% decrease in AM PEF, a >=70% increase in albuterol use, or the occurrence of an asthma exacerbation requiring oral steroids or hospitalization.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   12 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects eligible for enrollment in the study must meet all of the following criteria:

    1. Consent: A signed and dated written informed consent must be obtained from the subject and/or subject's legally acceptable representative prior to study participation.
    2. Type of Subject: Outpatient
    3. Gender: Male or female Females are eligible to participate only if they are currently non-pregnant and non-lactating.

A female is eligible to enter and participate in the study if she is:

  1. of non-child-bearing potential; OR
  2. of child-bearing potential but has a negative urinary pregnancy test at Screening (Visit 1 and when specified in Appendix 1) and agrees to take contraceptive precautions (including abstinence) which are adequate to prevent pregnancy during the study.

    Acceptable methods of contraception [Hatcher, 2004] are:

    - Abstinence

    • oral contraceptive (either combined or progestogen only)
    • injectable progestogen
    • implants of levonorgestrel
    • estrogenic vaginal ring
    • percutaneous contraceptive devices
    • intrauterine device (IUD) or intrauterine system (IUS) with published data showing that the lowest expected failure rate is less than 1% per year
    • male partner sterilization (vasectomy with documentation of azoospermia) prior to the female subject's entry into the study and is the sole sexual partner for that female subject
    • double barrier method: condom or occlusive cap (diaphragm or cervical/vault caps) plus spermicidal agent

      1. Age: A subject must be 12 years of age at Visit 1 (screening).
      2. Asthma Diagnosis: A documented diagnosis of persistent asthma, for at least six months, as defined by the following American Thoracic Society definition:

    Asthma is a clinical syndrome characterized by increased responsiveness of the airways to a variety of stimuli. The major symptoms of asthma are episodes of dyspnea, wheezing, and cough, which may vary from mild and almost undetectable to severe and unremitting (status asthmaticus). The primary physiological manifestation of this hyperresponsiveness is variable airway obstruction. This can take the form of spontaneous fluctuations in the severity of obstruction, substantial improvements in the severity of obstruction following bronchodilators or corticosteroids, or increased obstruction caused by drugs or other stimuli [American Thoracic Society, 1987].

    1. Asthma Medication History: A subject must be using a low to medium dose of an ICS (Table 1) OR a combination of controller medications (Table 2), containing a low (total daily) dose ICS (as defined in Table 1) for at least 4 weeks preceding screening.

    Table 1 (ICS Dosage Table) Inhaled Corticosteroid (Dosage (mcg/day))(LowMedium) Beclomethasone dipropionate CFC (168 = 504> 504 = 840) Beclomethasone dipropionate HFA (80 = 240>240 = 640) Triamcinolone acetonide (400 = 1000>1000 = 2000) Flunisolide (500 = 1000> 1000 = 2000) Fluticasone propionate inhalation aerosol (176 = 220> 220 = 440) Fluticasone propionate inhalation powder (100 = 250> 250 = 500) Budesonide1 (200 = 600> 600 =1200) Mometasone (200 = 400> 400 = 800) Ciclesonide (80 = 160>160 = 320)

    1.Respules are allowed at a dosage of 250-500mcg/day.

    Table 2 (Asthma Controller Medications) Asthma Controller Medication(s) Low dose ICS + Leukotriene modifiers Low dose ICS + Theophylline products Low Dose ICS + Inhaled anticholinergics or combination products (e.g., Atrovent or Combivent) Low Dose ICS + Long acting inhaled anticholinergic (e.g. Spiriva) Low dose ICS+ long acting beta agonist or combination products containing a low dose ICS and a long-acting beta-agonists (e.g. ADVAIR™/SERETIDE™1 100/50 mcg BID or Symbicort 160/9 mcg BID (i.e 80/4.5 mcg two inhalations BID)

    1.ADVAIR/SERETIDE =250/50 mcg BID or Symbicort 320/9 mcg BID (i.e 160/4.5 mcg two inhalation BID) are not permitted.

    1. Pulmonary function: A pre-albuterol (salbutamol) FEV1 of 50% and 85% of predicted normal value at screening (Visit 1) after withholding asthma medications as detailed in the protocol (Section 6.8.1). Predicted FEV1 will be based on the National Health and Nutrition Examination Survey (NHANES III) predicted normal values for ages 8 years and older [Hankinson, 1999].
    2. Reversibility: An increase in FEV1 of 12% over the pre-albuterol (salbutamol) FEV1 within 30 minutes after the inhalation of 2-4 puffs of albuterol (salbutamol). Historical documentation of reversibility will not be permitted.
    3. Asthma symptom criteria: Each subject must have experienced asthma symptoms requiring albuterol (salbutamol) use within the 4 weeks preceding screening (Visit 1).

    Specific information regarding warnings, precautions, contraindications, adverse events, and other pertinent information on the investigational product that may impact subject eligibility is provided in the IB and the product labels.

    Exclusion Criteria:

    • Subjects meeting any of the following criteria must not be enrolled in the study:

      1.Life-Threatening Asthma: A subject must not have life-threatening asthma. Life-threatening asthma is defined for this protocol as a history of significant asthma episode(s) requiring intubation associated with hypercapnia, respiratory arrest, or hypoxic seizures, or asthma-related syncopal episode(s) within the 12 months prior to screening (Visit 1).

      2.Worsening of Asthma: A subject must not have experienced a worsening of asthma which involved an ER visit, hospitalization or use of oral/parenteral corticosteroids within 4 weeks of screening (Visit 1).

      3.Intermittent, Seasonal, or Exercise-Induced Asthma Alone: Subjects with only intermittent or seasonal or exercise-induced asthma are excluded from participation in this study.

      4.Concurrent Respiratory Disease: A subject must not have current evidence of pneumonia, pneumothorax, atelectasis, pulmonary fibrotic disease, chronic bronchitis, emphysema, chronic obstructive pulmonary disease, or other respiratory abnormalities other than asthma.

      5.Concurrent Conditions/Diseases: A subject with historical or current evidence of any clinically significant, co-morbid or uncontrolled condition or disease state that, in the opinion of the investigator, would put the safety of the subject at risk through study participation or would confound the interpretation of the results if the condition/disease exacerbated during the study.

    The list of excluded conditions/diseases includes, but is not limited to:

    congestive heart failure known aortic aneurysm clinically significant coronary clinically significant cardiac arrhythmia heart disease stroke within 3 months of screening (Visit 1) uncontrolled hypertension coronary artery disease hematologic, hepatic, or renal disease cystic fibrosis poorly controlled peptic ulcer dyspnea by any other cause than asthma gastroesophageal reflux disease (GERD) not controlled by pharmacotherapy and may be causing/contributing to subject's respiratory symptoms thyrotoxicosis hypokalemia immunologic compromise current malignancy1 tuberculosis (current or quiescent) Cushing's or Addison's disease pneumonia, pneumothorax, chronic bronchitis or atelectasis uncontrolled diabetes mellitus recent history of drug or alcohol abuse 1.history of malignancy is acceptable only if subject has been in remission for one year prior to screening (Visit 1; remission = no treatment for the malignancy in the 12 months prior to screening [Visit 1])

    1. Drug Allergy: A subject must not have had any immediate or delayed hypersensitivity to any beta2-agonist; sympathomimetic drug; any intranasal; inhaled or systemic corticosteroid therapy; lactose; or have a severe milk protein allergy.
    2. Respiratory Tract Infections: A subject must not have had any sinus, middle ear, oropharyngeal, upper or lower respiratory tract infection symptoms that have not resolved at least 7 days immediately preceding screening (Visit 1).
    3. Asthma Medications: Asthma medications listed below must not have been used prior to screening (Visit 1) for the required exclusion period as indicated below:

      Medication (Exclusion Period Prior to screening (Visit 1)) Oral or parenteral systemic corticosteroids (4 weeks) Omalizumab (Xolair) (6 months)

    1. Concurrent Medications: A subject must not have the concurrent use of any of the following medications that interact with any of the study drugs used in this study, or that may affect the course of asthma or interact with sympathomimetic amines, such as:

      - beta-adrenergic receptor blocking agents

      - monoamine oxidase (MAO) inhibitors

      - tricyclic antidepressants

      - ritonavir

      • ketoconazole
    2. Concurrent use of asthma medications: Concurrent use of all asthma medications (other than protocol defined study and rescue medications and oral/parenteral corticosteroids) are prohibited during the study.
    3. Concomitant use of leukotriene modifiers (LTM) for allergies is prohibited. A subject must not be on LTM for treatment of nasal allergies that requires regular maintenance therapy. Substitution with any other antihistamine is permitted.
    4. Immunosuppressive Medications: A subject must not be using, or require the use of, immunosuppressive medications during the study.
    5. Immunotherapy for the treatment of allergies is not allowed during the study unless the subject has used a constant dose for 4 weeks prior to Screening (Visit 1) and the same dose will be continued throughout the study.
    6. Tobacco Use: >10 pack year history or use of any tobacco products within 1 year of screening (Visit 1). This includes cigarettes, cigars, pipe, chewing tobacco, and snuff.
    7. Questionable Validity of Consent: A subject must not have any infirmity or disability that would limit the subject's consent.
    8. Positive Pregnancy Test (for all females who have had menarche): A current positive pregnancy test.
    9. Investigational Medications: A subject must not have had use of any investigational drug within 30 days of screening (Visit 1).
    10. Site Affiliation: A subject may not participate if he/she is a participating investigator, sub-investigator, study coordinator, employee of a participating investigator or is in any way associated with the administration of the study. Immediate family members of these individuals are also excluded.
    11. Compliance with Study Requirements: A subject may not participate if, in the opinion of the investigator, there are present or anticipated circumstances that will prohibit the subject from being compliant with study visits and procedures (e.g. geographic location that will prohibit subject from required clinic visit schedule).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00452348

  Hide Study Locations
Layout table for location information
United States, Alabama
GSK Investigational Site
Birmingham, Alabama, United States, 35209
GSK Investigational Site
Birmingham, Alabama, United States, 35294
GSK Investigational Site
Mobile, Alabama, United States, 36608
United States, California
GSK Investigational Site
Fresno, California, United States, 93720
GSK Investigational Site
Fullerton, California, United States, 92835
GSK Investigational Site
Huntington Beach, California, United States, 92647
GSK Investigational Site
Long Beach, California, United States, 90808
GSK Investigational Site
Los Angeles, California, United States, 90048
GSK Investigational Site
San Diego, California, United States, 92120
GSK Investigational Site
Stockton, California, United States, 95207
GSK Investigational Site
Vista, California, United States, 92083
United States, Colorado
GSK Investigational Site
Pueblo, Colorado, United States, 81008
United States, Florida
GSK Investigational Site
Hudson, Florida, United States, 34667
GSK Investigational Site
South Miami, Florida, United States, 33143
GSK Investigational Site
Tampa, Florida, United States, 33613
United States, Georgia
GSK Investigational Site
Albany, Georgia, United States, 31707
GSK Investigational Site
Gainesville, Georgia, United States, 30501
GSK Investigational Site
Lawrenceville, Georgia, United States, 30045
GSK Investigational Site
Savannah, Georgia, United States, 31406
United States, Idaho
GSK Investigational Site
Coeur D'Alene, Idaho, United States, 83814
United States, Indiana
GSK Investigational Site
Evansville, Indiana, United States, 47710
United States, Kentucky
GSK Investigational Site
Owensboro, Kentucky, United States, 42301
United States, Louisiana
GSK Investigational Site
Sunset, Louisiana, United States, 70584
United States, Minnesota
GSK Investigational Site
Rochester, Minnesota, United States, 55905
United States, Missouri
GSK Investigational Site
Chesterfield, Missouri, United States, 63017
GSK Investigational Site
Jefferson City, Missouri, United States, 65101
United States, Montana
GSK Investigational Site
Missoula, Montana, United States, 59808
United States, Nebraska
GSK Investigational Site
Lincoln, Nebraska, United States, 68505
GSK Investigational Site
Papillion, Nebraska, United States, 68046
United States, New Jersey
GSK Investigational Site
Ocean, New Jersey, United States, 07712
United States, New York
GSK Investigational Site
New York, New York, United States, 10016
United States, North Carolina
GSK Investigational Site
Charlotte, North Carolina, United States, 28207
GSK Investigational Site
Winston-Salem, North Carolina, United States, 27103
United States, North Dakota
GSK Investigational Site
Fargo, North Dakota, United States, 58104
United States, Ohio
GSK Investigational Site
Canton, Ohio, United States, 44718
United States, Oklahoma
GSK Investigational Site
Oklahoma City, Oklahoma, United States, 73120
United States, Oregon
GSK Investigational Site
Lake Oswego, Oregon, United States, 97035
GSK Investigational Site
Medford, Oregon, United States, 97504
United States, Pennsylvania
GSK Investigational Site
Collegeville, Pennsylvania, United States, 19426
GSK Investigational Site
Erie, Pennsylvania, United States, 16508
GSK Investigational Site
Philadelphia, Pennsylvania, United States, 19102
United States, Rhode Island
GSK Investigational Site
Cumberland, Rhode Island, United States, 02864
United States, South Carolina
GSK Investigational Site
Charleston, South Carolina, United States, 29406-7108
GSK Investigational Site
Greenville, South Carolina, United States, 29615
GSK Investigational Site
Greer, South Carolina, United States, 29651
United States, Texas
GSK Investigational Site
El Paso, Texas, United States, 79903
GSK Investigational Site
Houston, Texas, United States, 77070
GSK Investigational Site
Killeen, Texas, United States, 76542
GSK Investigational Site
San Antonio, Texas, United States, 78229
GSK Investigational Site
Waco, Texas, United States, 76712
United States, Utah
GSK Investigational Site
Murray, Utah, United States, 84107
United States, Virginia
GSK Investigational Site
Norfolk, Virginia, United States, 23507
United States, Washington
GSK Investigational Site
Gig Harbor, Washington, United States, 98335
GSK Investigational Site
Tacoma, Washington, United States, 98405
United States, West Virginia
GSK Investigational Site
Morgantown, West Virginia, United States, 26505
United States, Wisconsin
GSK Investigational Site
Greenfield, Wisconsin, United States, 53228
GSK Investigational Site
Madison, Wisconsin, United States, 53972
GSK Investigational Site
Milwaukee, Wisconsin, United States, 53209
GSK Investigational Site
Rosario, Santa Fe, Argentina, 2000
GSK Investigational Site
Buenos Aires, Argentina, 1221
GSK Investigational Site
Buenos Aires, Argentina, 1437
GSK Investigational Site
Ciudad Autónoma de Buenos Aires, Argentina, C1121ABE
GSK Investigational Site
Mendoza, Argentina, M5500CCG
GSK Investigational Site
Santa Fe, Argentina, 3000
GSK Investigational Site
Tucuman, Argentina, 4000
GSK Investigational Site
Porto Alegre, Rio Grande Do Sul, Brazil, 90610-000
GSK Investigational Site
Florianopolis, Santa Catarina, Brazil
GSK Investigational Site
Santo Andre, São Paulo, Brazil, 09060-670
GSK Investigational Site
Rio de Janeiro, Brazil, 20221-903
GSK Investigational Site
São Paulo, Brazil, 04079002
Canada, British Columbia
GSK Investigational Site
Vancouver, British Columbia, Canada, V5Z 1K3
Canada, New Brunswick
GSK Investigational Site
Moncton, New Brunswick, Canada, E1C 2Z3
Canada, Ontario
GSK Investigational Site
Kitchener, Ontario, Canada, N2C 2N9
GSK Investigational Site
Newmarket, Ontario, Canada, L3Y 5G8
GSK Investigational Site
Oshawa, Ontario, Canada, L1H 7K4
GSK Investigational Site
Toronto, Ontario, Canada, M9V 4B4
Canada, Quebec
GSK Investigational Site
Saint Leonard, Quebec, Canada, H1S 3A9
GSK Investigational Site
Sainte-Foy, Quebec, Canada, G1W 4R4
GSK Investigational Site
St-Romuald, Quebec, Canada, G6W 5M6
GSK Investigational Site
Quezon City, Philippines, 1101
GSK Investigational Site
Quezon City, Philippines, 1109
Sponsors and Collaborators
Layout table for investigator information
Study Director: GSK Clinical Trials GlaxoSmithKline

Additional Information:
Study Data/Documents: Statistical Analysis Plan  This link exits the site
Identifier: ADA109057
For additional information about this study please refer to the GSK Clinical Study Register
Dataset Specification  This link exits the site
Identifier: ADA109057
For additional information about this study please refer to the GSK Clinical Study Register
Individual Participant Data Set  This link exits the site
Identifier: ADA109057
For additional information about this study please refer to the GSK Clinical Study Register
Clinical Study Report  This link exits the site
Identifier: ADA109057
For additional information about this study please refer to the GSK Clinical Study Register
Informed Consent Form  This link exits the site
Identifier: ADA109057
For additional information about this study please refer to the GSK Clinical Study Register
Study Protocol  This link exits the site
Identifier: ADA109057
For additional information about this study please refer to the GSK Clinical Study Register
Annotated Case Report Form  This link exits the site
Identifier: ADA109057
For additional information about this study please refer to the GSK Clinical Study Register

Kerwin E, Prazma CM, Sutton L, Stempel DA. Safety and efficacy of long-term treatment with fluticasone propionate and salmeterol via DISKUS versus fluticasone propionate alone. Clin Res Reg Aff 2011;28(1):14-21.

Layout table for additonal information
Responsible Party: GlaxoSmithKline Identifier: NCT00452348     History of Changes
Other Study ID Numbers: ADA109057
First Posted: March 27, 2007    Key Record Dates
Results First Posted: February 15, 2010
Last Update Posted: December 9, 2016
Last Verified: October 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Patient-level data for this study will be made available through following the timelines and process described on this site.
Keywords provided by GlaxoSmithKline:
12 month
Additional relevant MeSH terms:
Layout table for MeSH terms
Salmeterol Xinafoate
Fluticasone-Salmeterol Drug Combination
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Anti-Inflammatory Agents
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Dermatologic Agents
Anti-Allergic Agents
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Hormones, Hormone Substitutes, and Hormone Antagonists